Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of atogepant for prevention of migraine in Japanese participants
jRCT2080225228Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atogepant in chronic migraine and migraine, sponsored by AbbVie Inc. Primary endpoint: Long-term safety and tolerability of atogepant. Started Jun 2020; status: completed.
02
Drugs
atogepant
03
Conditions
chronic migrainemigraine
Beyond the preview
Go deeper on jRCT2080225228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225228.